News
INCPF
2.050
NaN%
--
InnoCare Pharma Names New Joint Company Secretary and Secures Listing Rules Waiver
TipRanks · 4d ago
InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
TipRanks · 05/28 21:07
InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator
TipRanks · 05/28 08:40
InnoCare Wins Australian Approval for Lymphoma Drug Orelabrutinib
TipRanks · 05/27 09:13
Shenwan Hongyuan Remains a Buy on InnoCare Pharma Ltd. (9969)
TipRanks · 05/14 05:26
InnoCare Starts First-in-Human Trial of Oral IL-17 Inhibitor ICP-054
TipRanks · 05/13 11:20
InnoCare Pharma Ltd. (9969) Receives a Buy from UBS
TipRanks · 04/25 00:25
InnoCare Pharma Sets 2026 AGM to Approve 2025 Results and Renew Share Issuance Mandate
TipRanks · 04/24 14:39
InnoCare Pharma Grants RSUs Tied to Revenue and R&D Milestones
TipRanks · 04/24 13:38
InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver
TipRanks · 04/24 13:38
InnoCare: Strong Orelabrutinib Uptake and Autoimmune Pipeline Drive Target Price Upgrade and Buy Rating
TipRanks · 04/24 10:26
InnoCare Pharma Issues Unaudited PRC-GAAP Q1 2026 Report for STAR Market Compliance
TipRanks · 04/23 11:11
InnoCare Pharma Sets April Board Meeting to Approve Q1 2026 Results
TipRanks · 04/10 09:07
InnoCare Pharma Ltd. (9969) Gets a Buy from UBS
TipRanks · 03/27 00:27
InnoCare Pharma Moves to Modernize Governance With New Corporate Charter
TipRanks · 03/25 11:41
InnoCare Tightens Audit Committee Rules to Bolster Governance
TipRanks · 03/25 11:40
InnoCare Pharma Tightens Governance With Formal Compensation Committee Mandate
TipRanks · 03/25 11:39
InnoCare Pharma Updates Nomination Committee Governance Framework
TipRanks · 03/25 11:39
InnoCare Pharma Swings to Profit on Surging Drug Sales and Licensing Revenue
TipRanks · 03/25 11:09
InnoCare Pharma Adjusts Internal Allocation of STAR Market Share Proceeds
TipRanks · 03/25 11:08
More
Webull provides a variety of real-time INCPF stock news. You can receive the latest news about Innocare Pharma through multiple platforms. This information may help you make smarter investment decisions.
About INCPF
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.